who is making retatrutide The next big shift in obesity care may not be surgery — it may be a weekly shot. Retatrutide, an investigational triple-action medicine, showed 28.3% average body-weight loss over 80 weeks in Retatrutide – new weight loss

According to the FDA approval announcement, Zepbound (tirzepatide) represents a breakthrough in obesity treatment as the first and only FDA-approved weight loss medication that targets two distinct hormone receptors simultaneously

Emphasizes protein-first nutrition for muscle and appetite support

Its time to get the relief you need

Patients who are struggling to build meals around a smaller appetite may benefit from nutritional counseling and coaching rather than relying on a generic list of "GLP-1 foods." MTC's nutrition service focuses on personalized eating guidance and health goals

Individual Case Reports: The Encouraging Stories Several detailed case reports have been published documenting individual pregnancy outcomes after GLP-1 exposure

This concentrated urine can appear cloudy and have a stronger odor